Cite
HARVARD Citation
Passamonti, F. et al. (n.d.). Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet oncology. 18 (1), pp. 88-99. [Online].